[
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
    "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at […]",
    "url": "https://finnhub.io/api/news?id=dcf81e350fe0e20c9bff3874e77eee1ece4cb69a791d27819adca64689389f53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734436752,
      "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Weight Loss Stock to Buy Now According to Hedge Funds?",
      "id": 132024280,
      "image": "https://s.yimg.com/ny/api/res/1.2/ZsrqNB_sdV78LPtS9DZ12A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at […]",
      "url": "https://finnhub.io/api/news?id=dcf81e350fe0e20c9bff3874e77eee1ece4cb69a791d27819adca64689389f53"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline",
    "summary": "As previously reported, Jefferies upgraded Bristol Myers (BMY) to Buy from Hold with a price target of $70, up from $63. The firm thinks Cobenfy can become a $10B-plus drug, is getting “increasingly more confident” that Milvexian could hit on non-inferiority and has gotten more visibility on profit-and-loss and thinks the thesis that the EPS floor will break $6 is “gone,” noting that it sees an EPS trough in 2029 or earlier with operating leverage. Published first on TheFly – the ultimate source",
    "url": "https://finnhub.io/api/news?id=11a0766a29adf93ece73069e201c416ecc31a6234a7ef3cb86cf59b6c12c5d65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734435054,
      "headline": "Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline",
      "id": 132023652,
      "image": "https://media.zenfs.com/en/tipranks_452/67452c7ec1c6f468e4f6ed21d46c455f",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "As previously reported, Jefferies upgraded Bristol Myers (BMY) to Buy from Hold with a price target of $70, up from $63. The firm thinks Cobenfy can become a $10B-plus drug, is getting “increasingly more confident” that Milvexian could hit on non-inferiority and has gotten more visibility on profit-and-loss and thinks the thesis that the EPS floor will break $6 is “gone,” noting that it sees an EPS trough in 2029 or earlier with operating leverage. Published first on TheFly – the ultimate source",
      "url": "https://finnhub.io/api/news?id=11a0766a29adf93ece73069e201c416ecc31a6234a7ef3cb86cf59b6c12c5d65"
    }
  }
]